@article{oai:nagasaki-u.repo.nii.ac.jp:00000080,
 author = {Takazono, Takahiro and Tashiro, Masato and Ota, Yuki and Obata, Yoko and Wakamura, Tomotaro and Miyazaki, Taiga and Nishino, Tomoya and Izumikawa, Koichi},
 issue = {1},
 journal = {Scientific Reports},
 month = {Sep},
 note = {Liposomal amphotericin B (L-AMB) is a broad-spectrum antifungal drug that is used to treat fungal infections. However, clinical evidence of its use in patients with renal failure is limited. Here, we aimed to identify factors associated with acute kidney injury (AKI) in patients administered L-AMB. We retrospectively utilized a combination of Diagnosis Procedure Combination data and laboratory data obtained from hospitals throughout Japan between April 2008 and January 2018. In total, 507 patients administered L-AMB were identified. After L-AMB treatment initiation, AKI, which was defined as a???1.5-fold increase within 7 days or???0.3 mg/dL increase within 2 days in serum creatinine according to the KDIGO criteria, was recognized in 37% of the total patients (189/507). The stages of AKI were stage 1 in 20%, stage 2 in 11%, and stage 3 in 7%. Five factors were associated with AKI of all stages: prior treatment with angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers or carbapenem; concomitant administration of catecholamines or immunosuppressants; and???3.52 mg/kg/day of L-AMB dosing. Serum potassium?<?3.5 mEq/L before L-AMB therapy was associated with severe AKI of stage 2 and 3. Altogether, these factors should be carefully considered to reduce the occurrence of AKI in patients administered L-AMB., Scientific Reports, 10(1), art.no.15033; 2020},
 title = {Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan},
 volume = {10},
 year = {2020}
}